Skip to main content

Table 1 Demographic characteristics of the patients with juvenile idiopathic arthritis at the time of diagnosis and 1 year after the diagnosis

From: Myeloid-related protein 8/14 in plasma and serum in patients with new-onset juvenile idiopathic arthritis in real-world setting in a single center

  Number of patients (%)    
Female sex, n (%) 62 (71)    
HLA-B27 positivity, n (%) 23 (26)    
Antinuclear antibody positivity, titer > or = 160, n (%) 41 (47)    
JIA subtype, n (%)     
Oligoarthritis, persistent 29 (33)    
Oligoarthritis, extended 4 (4.5)    
Polyarthritis, seronegative 43 (49)    
Polyarthritis, seropositive 3 (3.5)    
Enthesitis-related arthritis 8 (9)    
Psoriatic arthritis 1 (1)    
  At diagnosis   At one year  
  Median (IQR) Mean (SD) Median (IQR) mean (SD)
Age at diagnosis, years 5.8 (4.7–9.6) 6.6 (4.3)   
Duration of arthritis symptoms at diagnosis, days 87 (47–185.5) 179 (276)   
Active joint count 3 (1–8) 7 (9) 0 (0–1) 1 (4)
Physician’s global assessment, VAS 0 to 100 mm 21 (11–36) 25 (18) 2 (0–8) 6 (11)
Patient’s/parent’s assessment of global well-being, VAS  0 to 100 mm 16 (5–35) 22 (20) 3 (0–13.3) 9 (13)
CHAQc 0 (0–0.38) 0.2 (0.4) 0 (0–0.13) 0.1 (0.2)
Erytrocyte sedimentation rate, mm/h 13 (7–28) 20 (21) 6 (3–8) 8 (9)
C-reactive protein, mg/l 2 (2–17) 14 (28) 2 (2–2) 5 (19)
Leucocytes E9/l 7.4 (6.1–9.7) 8.1 (2.8) 5.8 (4.8–7.7) 6.3 (2.0)
Neutrophils E9/l 3.8 (2.8–5.1) 4.2 (2.0) 2.5 (2.0–3.7) 2.8 (1.2)
MRP8/14d in serum, ng/ml 252 (180–317) 257 (115) 174 (113–244) 183 (103)
MRP8/14 in plasma, ng/ml 192 (100–344) 229 (168) 77 (100–136) 99 (91)
MRP8/14 in synovial fluid, ng/ml 1304 (993–1500) 1292 (409)   
  1. Data are either median (IQR), mean (SD) or n (%) where indicated. HLA-B27 Human leucocyte antigen B27, VAS Visual analogue scale, CHAQ Childhood health assessment questionnaire, MRP8/14 Myeloid-related protein 8/14